

March 5, 2019



## Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

**DURHAM, NC / ACCESSWIRE / March 5, 2019/ [Heat Biologics, Inc.](http://www.heatbio.com)** (NASDAQ: HTBX), a biopharmaceutical company developing "off-the-shelf" T-cell therapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, will chair a roundtable discussion at 4:00-5:00 pm China Standard Time (CST), on Wednesday, March 6, 2019 at the WuXi Healthcare Forum at the St. Regis Shanghai Jingan Hotel. The Forum brings together more than 5,000 industry leaders from 2,000 organizations spanning 20 countries to share their collective insights on the global challenges facing healthcare and future possibilities.

Dr. Prendergast will chair a panel on oncology, which will focus on promising new developments in the space.

### **About Heat Biologics, Inc.**

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our *ComPACT* technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit [www.heatbio.com](http://www.heatbio.com).

### **Forward Looking Statements**

*This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the suggestion that the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor and the suggestion that HS-110 may improve*

*outcomes for patients who are least likely to benefit from treatment with checkpoint inhibitors alone. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and its ability to retain its key scientists or management personnel, and the other factors described in Heat's filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.*

Media and Investor Relations Contact

David Waldman

+1 919 289 4017

[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

**SOURCE:** Heat Biologics, Inc.